Brookline Capital Management Equities Analysts Lower Earnings Estimates for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Brookline Capital Management dropped their FY2028 earnings per share estimates for shares of Syros Pharmaceuticals in a research report issued to clients and investors on Tuesday, June 25th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of $11.37 for the year, down from their previous estimate of $11.61. The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($3.19) per share.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same quarter in the prior year, the firm posted ($0.85) earnings per share.

SYRS has been the subject of a number of other research reports. StockNews.com upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 15th. Piper Sandler restated an “overweight” rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a report on Wednesday, April 3rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Syros Pharmaceuticals in a research note on Wednesday.

Syros Pharmaceuticals Stock Down 1.7 %

SYRS stock opened at $5.70 on Thursday. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $8.17. The business has a 50 day simple moving average of $5.27 and a 200-day simple moving average of $6.06. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.01 and a quick ratio of 3.01.

Institutional Trading of Syros Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bain Capital Life Sciences Investors LLC lifted its position in shares of Syros Pharmaceuticals by 29.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company’s stock worth $21,421,000 after purchasing an additional 625,114 shares in the last quarter. Avidity Partners Management LP grew its stake in shares of Syros Pharmaceuticals by 5.8% during the fourth quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company’s stock valued at $13,037,000 after acquiring an additional 92,396 shares in the last quarter. Flagship Pioneering Inc. increased its position in shares of Syros Pharmaceuticals by 30.2% during the fourth quarter. Flagship Pioneering Inc. now owns 1,293,848 shares of the company’s stock worth $10,079,000 after acquiring an additional 300,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Syros Pharmaceuticals by 21.3% during the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after purchasing an additional 163,234 shares during the last quarter. Finally, Opaleye Management Inc. boosted its stake in shares of Syros Pharmaceuticals by 119.1% during the 1st quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock valued at $4,213,000 after buying an additional 428,175 shares during the last quarter. Institutional investors and hedge funds own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.